Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of ALG-097558 in Subjects With Renal Impairment and Normal Renal Function
NCT06698549Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALG-097558 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area Under the Concentration Time Curve at Day 8, Maximum Plasma Concentration at Day 8 and 8 more. Started Feb 2025; status: completed.
02
Drugs
ALG-097558
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06698549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698549.